Will Herrington is a Medical Research Council-Kidney Research UK Professor David Kerr clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’.

Will now aims to better understand the key determinants of kidney disease development and progression using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease. He is also interested in incorporating more routine healthcare data and mobile technology into large-scale renal epidemiology and streamlined trials.

Will co-leads the EMPA-KIDNEY study, a trial testing the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 5000 people with chronic kidney disease with and without diabetes.

Will collaborates with the Mexico City Prospective Study, the Cholesterol Treatment Trialists’ Collaboration, UK Biobank, China-Kadoorie Biobank, and the Prospective Studies Collaboration. He is module co-lead for the Record Linkage and Bioinformatics module in the department’s MSc in Global Health Science. He has also advised the Kidney Health Initiative, the Clinical Trials Transformation Initiative and was Scientific Co-ordinator for the KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology.